Abstract:RNA interference (RNAi) provides researchers with a versatile means to modulate target gene expression. The major forms of RNAi molecules, genome-derived microRNAs (miRNAs) and exogenous small interfering RNAs (siRNAs), converge into RNA-induced silencing complexes to achieve posttranscriptional gene regulation. RNAi has proven to be an adaptable and powerful therapeutic strategy where advancements in chemistry and pharmaceutics continue to bring RNAi-based drugs into the clinic. With four siRNA medications already approved by the US Food and Drug Administration (FDA), several RNAi-based therapeutics continue to advance to clinical trials with functions that closely resemble their endogenous counterparts. Although intended to enhance stability and improve efficacy, chemical modifications may increase risk of off-target effects by altering RNA structure, folding, and biologic activity away from their natural equivalents. Novel technologies in development today seek to use intact cells to yield true biologic RNAi agents that better represent the structures, stabilities, activities, and safety profiles of natural RNA molecules. In this review, we provide an examination of the mechanisms of action of endogenous miRNAs and exogenous siRNAs, the physiologic and pharmacokinetic barriers to therapeutic RNA delivery, and a summary of the chemical modifications and delivery platforms in use. We overview the pharmacology of the four FDA-approved siRNA medications (patisiran, givosiran, lumasiran, and inclisiran) as well as five siRNAs and several miRNA-based therapeutics currently in clinical trials. Furthermore, we discuss the direct expression and stable carrier-based, in vivo production of novel biologic RNAi agents for research and development. SIGNIFICANCE STATEMENT In our review, we summarize the major concepts of RNA interference (RNAi), molecular mechanisms, and current state and challenges of RNAi drug development. We focus our discussion on the pharmacology of US Food and Drug Administration-approved RNAi medications and those siRNAs and miRNA-based therapeutics that entered the clinical investigations. Novel approaches to producing new true biological RNAi molecules for research and development are highlighted.

RNA‐based medicine: from molecular mechanisms to therapy

RNA-based Therapeutics: an Overview and Prospectus

Recent Advances and Prospects in RNA Drug Development

Innovative developments and emerging technologies in RNA therapeutics

RNA-based nanomedicines and their clinical applications

Frameworks for transformational breakthroughs in RNA-based medicines

RNA therapeutics: Molecular mechanisms, and potential clinical translations

Current Advances in RNA Therapeutics for Human Diseases

RNA therapeutics in the clinic

RNA Therapeutics - Research and Clinical Advancements

The Limitless Future of RNA Therapeutics

RNA Cancer Nanomedicine: Nanotechnology-Mediated RNA Therapy.

RNAi-Based Therapeutics and Novel RNA Bioengineering Technologies

The current state and future directions of RNAi-based therapeutics

Advances in RNA therapeutics for modulation of 'undruggable' targets

RNA interference in the era of nucleic acid therapeutics

RNA in Therapeutics: CRISPR in the Clinic

RNA interference: from an ancient mechanism to a state of the art therapeutic application?

From the RNA world to the clinic

RNA therapy: Are we using the right molecules?

The current perspective and opportunities of small nucleic acid‐based therapeutics